Abstract: The present invention relates to a composition for promoting eye health in a companion animal. The composition comprising: at least one polyphenol selected from the group consisting of rosemary, rosemary extract, coffeic acid, coffee extract, turmeric extract, cucurmin, blueberry extract, grapeseed extract, rosemarinic acid, tea extract, and mixtures thereof.

Abstract: Provided are compositions and methods for modulating quorum sensing in microbes. The compounds are AI-2 analogs and as such have structures similar to 4,5-dihydroxy-2,3-pentanedione that can act as agonists/antagonists of quorum sensing. The compounds are useful for modulating quorum sensing in bacteria and can be used in methods for prophylaxis or therapy of bacterial infections and for reduction of biofilms.

Abstract: The present invention relates to the use of polyunsaturated fatty acids and one or more components which have a beneficial effect on total methionine metabolism selected from the group consisting of vitamin B12 and precursors thereof, vitamin B6 and derivatives thereof, folic acid, zinc and magnesium, in the manufacture of a preparation for improving the action of receptors. This preparation is advantageously applied in patients suffering from Parkinson's disease, Huntington's chorea, epilepsy, schizophrenia, paranoia, depression, sleep disorders, impaired memory function, psychoses, dementia and ADHD.

Abstract: The present invention relates to a compound represented by the formula (A) or (B), or a salt thereof capable of improving a red color of pyrroloquinoline quinone (PQQ) and obtaining functions of original PQQ, and to a method of efficiently manufacturing the compound. wherein R is an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group, or an alkoxyalkyl group.

Abstract: The present invention relates to a process for preparing cyclic compounds having at least eight carbon atoms and at least one keto group, to the cyclic compounds obtained by this process and to the use thereof, in particular as fragrance or for providing a fragrance.

Abstract: The present invention provides compositions comprising sugar, cysteine, and/or sugar-cysteine products, methods of preparing the same, and/or using the same.

Abstract: The present invention provides methods and compositions for treating leukemia by cyclohexenone compounds.

Abstract: Methods and formulations for treating oncological disorders in humans using Coenzyme Q10 are described.

Abstract: The present invention is directed to therapeutic methods and compositions involving cyclohexenone compounds where said compounds inhibit farnesyltransferase or Ras. The therapeutic methods (e.g. for treating cancers) comprise contacting a tumor with a cyclohexenone compound and an anticancer agent.

Abstract: The formulations of the present disclosure alter the perception of symptoms, especially as experienced by subjects reporting the characteristic features associated with the syndrome known as multiple chemical sensitivity (MCS). The present disclosure encompasses formulations for the relief of symptoms associated with MCS, where the formulations comprise orthophosphoric acid, a vegetable oil comprising an esterified mono-unsaturated fatty acid, folic acid, and a molybdenum salt. The formulations can further comprise magnesium citrate, magnesium aspartate, malic acid, L-carnitine, alpha-ketoglutaric acid, co-enzyme Q10, glycerol, inositol, and choline bitartrate, optionally Q10, and riboflavin to provide a yellow color to the formulation. Another aspect of the disclosure are methods for alleviating MCS-related symptoms in subject human, comprising: providing to a subject an effective dose of a formulation comprising orthophosphoric acid, a mono-unsaturated fat, folic acid, molybdenum, and water.

Abstract: The present invention relates to a composition for oral use in the treatment of gastrointestinal pathologies comprising silicone antifoaming agents in an oily solvent medium, wherein the concentration of said silicone antifoaming agents is between 0.1% and 80% by weight.

Abstract: The present disclosure relates to a method of inducing apoptosis in a cancer cell by delivery of exogenous Coenzyme Q1O or its metabolites thereof in a pharmaceutically acceptable carrier to effectuate cell contact of endogenous Coenzyme Q1O or its metabolites thereof in addition to but not limited to mevalonic acid and oleic add to form an intracellular complex. The present disclosure also provides a method of modulating the p53 pathway and Bcl-2 protein family in a manner that restores the apoptotic potential to a cancer cell by delivery of Coenzyme Q1O in a pharmaceutically acceptable carrier. The present disclosure further provides a method to specifically normalize the ratio of pro-apoptotic and anti-apopotic members of the Bcl-2 gene family in a proportion to re-program a cancer cell to undergo apoptosis.

Abstract: A formulation or composition contractility comprising jasmonate for modulating bladder and/or treating bladder dysfunction, particularly an overactive bladder in a mammal, particularly a human and use of jasmonate for treating bladder dysfunction is provided.

Abstract: The present invention relates to a transmucosal administration system to administer quinones, benzoquinones, and especially 1,4-benzoquinones, via the oromucosal route.

Abstract: The present invention relates a process of production of beadlets comprising at least one hop acid salt in a matrix comprising at least one protein, to such beadlets and to the use of such specific beadlets in feed as well as in feed premixes.

Abstract: The invention relates to the use of a molecule selected from the group which consists of geranyl acetate, geraniol, isomenthone, limonene or a mixture of at least two of the above, for preparing a drug for treating or preventing vascular endothelial cell senescence and subjacent tissue degeneration induced by repeated inflammatory episodes. Specifically, the drug is useful for treating vascular endothelial cell senescence and tissue degeneration induced by repeated inflammatory episodes resulting from the presence of cancer cells.

Abstract: Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro or in vivo from cells of the GI tract of an individual.

Abstract: Nutritional products having improved cohesiveness of food boluses and methods of making and using same are provided. The nutritional products may include nutritional compositions and high molecular weight, water-soluble polymers such that the nutritional products have extensional viscosities that provide improved cohesiveness to the nutritional products and Trouton ratios of at least 6. Methods of administering such nutritional products to patients having impaired swallowing ability and/or dysphagia are also provided.

Abstract: A treatment is described for diseases with symptoms that can include fatigue, muscle aches and spasms, weakness, demylenation, and nerve pain. Diseases can include fibromyalgia, depression, and auto-immune and immuno-suppressive diseases, such as MS. The treatment comprises about 1-10 mg naltrexone, at least about 20 ?g vitamin B12, at least about 5 mg vitamin B6, at least about 2 mg coenzyme Q, and preferably at least one ancillary medication selected from the group consisting of diazepam, cyclcobenzaprine, clonazepam, alprazolam, 9-tetrahydrocannibinol, fumarate, caffeine, and combinations thereof. The treatment can be administered orally, and can decrease mental and physical symptoms such as, for example, fatigue, gait problems, visual dysfunction, and pain while improving cognitive skills.

Abstract: The present invention provides methods of treating humans and animals with terpenes and terpenoids in order to rejuvenate the skin and increase the protective layer against irradiation by ultraviolet radiation (UVR). More specifically it provides terpenes and terpenoids as ingredients that work as persistent UVR blockers. Terpenes and terpenoid compounds support the growth of skin, skin tissue and keratinocytes and additional UVR-blocking by reason of increased stratum corneum thickness and loricrin content. Both terpenes and terpenoids may be applied topically or orally at oral or topical concentrations from about 6 mg to about 600 mg per kilogram of body weight per day effective to stimulate growth of the skin layer and prevent damage from ultraviolet radiation (UVR).

Abstract: The present invention refers to thymoquinone, a main constituent of the volatile oil of Nigella sativa, and its protective effect against sepsis syndrome morbidity, mortality and associated organ dysfunctions. In particular, the present invention refers to thymoquinone for use in the prevention and/or treatment of sepsis syndrome. The present invention further refers to a pharmaceutical composition and a kit.

Abstract: The present invention relates to methods of treating Leigh Syndrome and Leigh-like Syndrome with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.

Abstract: The present invention is directed to pest-controlling compositions comprising as active ingredients one or more ?-diones, particularly ?-diketones and ?-triketones, and to the use of these compositions inter alia for preventing, eradicating, destroying, repelling or mitigating harmful, annoying or undesired pests including insects, arachnids, helminths, molluscs, protozoa and viruses. The present invention is further directed to processes of preparing ?-diones by de novo synthesis or from natural sources such as volatile oil-bearing plants from families including Alliaceae, Apiaceae, Asteraceae, Cannabinaceae, Lamiaceae, Pteridaceae, Myrtaceae, Myoporaceae, Proteaceae, Rutaceae and Zingiberaceae.

Abstract: Disclosed is a compound isolated from Antrodia camphorata, represented by formula I: wherein R1 is a hydrogen atom or an acetyl group; and a method of inhibiting cancer cell growth by using the compound, the cancer is selected from the group consisting of lung cancer, colon cancer, prostate cancer, liver cancer and breast cancer.

Abstract: The present invention concerns an antiviral composition comprising the following components: R-(?)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (?) carvone) and S-(+)-2-methyl-5-(prop-1-en-2-yl)-cyclohex-2-enone (also called (+) carvone) and (2E)-3,7-dimethylocta-2,6-dien-1-ol (also called trans-geraniol) in combination with at least one more component chosen among essential oils components for use in treatment and prevention of diseases caused by DNA enveloped viruses, DNA non-enveloped viruses, RNA enveloped viruses and RNA non-enveloped viruses.

Abstract: An aqueous suspension of a hydrophobic nutrient is disclosed. In particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension.

Abstract: Control and repellency of biting flies, house flies, ticks, ants, fleas, biting midges, cockroaches, spiders and stink bugs is obtained by contact of the insects with at least one of the compounds of the structure (I).

Abstract: A composition based on ubidecarenone, or coenzyme Q10 or CoQ10, comprises CoQ10, one or more specific hydrophylic carriers selected from the maltodextrins class and one or more adjuvant agents selected from the sucrose-esters class.

Abstract: The present invention relates to a composition consisting of Vitamin C, L-glutamine, L-cystine or L-cysteine, riboflavin, succinic acid, fumaric acid, coenzyme Q10, and niacin. The present invention relates further to the use of the composition for minimizing the cell-damaging effect of radicals and harmful forms of oxygen, in particular of oxygen radicals or reactive oxygen species. The present invention relates to a composition comprising Vitamin C, L-glutamine, L-cystine or L-cysteine, riboflavin, succinic acid, fumaric acid, coenzyme Q10, and niacin, wherein the composition is administered in a concentration ranging from 10 to 20 mg/kg body weight. The present invention relates further to the composition for use in the treatment and/or prevention of radical and harmful forms of oxygen derived diseases, in particular of oxygen radical or reactive oxygen species derived diseases. The present invention relates further to the composition as a food supplement or dietary supplement.

Abstract: Disclosed are compositions of matter useful for the treatment of elevated blood cholesterol. In one embodiment a nutraceutical composition is administered to a patient in need of said composition comprising of the following combination of ingredients: policosanol, niacin, guggul, garlic, cynara scolymus, red yeast rice, ginger, holy basil, L-carnitine, chromium picolinate, coenzyme Q10, pantothenic acid, grape seed extract, momordica charantia, and garcinia indica.

Abstract: The formulations of the present disclosure alter the perception of symptoms, especially as experienced by subjects reporting the characteristic features associated with the syndrome known as multiple chemical sensitivity (MCS). The present disclosure encompasses formulations for the relief of symptoms associated with MCS, where the formulations comprise orthophosphoric acid, a vegetable oil comprising an esterified mono-unsaturated fatty acid, folic acid, and a molybdenum salt. The formulations can further comprise magnesium citrate, magnesium aspartate, malic acid, L-carnitine, alpha-ketoglutaric acid, co-enzyme Q10, glycerol, inositol, and choline bitartrate, optionally Q10, and riboflavin to provide a yellow color to the formulation. Another aspect of the disclosure are methods for alleviating MCS-related symptoms in subject human, comprising: providing to a subject an effective dose of a formulation comprising orthophosphoric acid, a mono-unsaturated fat, folic acid, molybdenum, and water.

Abstract: The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders.

Abstract: The present invention provides an ophthalmic aqueous composition having an oil-in-water emulsion including a vegetable oil, a non-ionic surfactant, and a terpenoid, wherein an average particle diameter of emulsion particles is within the range of 30 nm to 300 nm.

Abstract: Disclosed is a cosmetic or dermatological formulation comprising a) at least one polyol in a concentration of from 0.1 to 20% by weight, based on the total weight of the formulation, and b) at least one diol selected from 2-methyl-1,3-propanediol, pentanediol, and hexanediol, in a concentration of from 0.1 to 25% by weight, based on the total weight of the formulation.

Abstract: The present invention provides an aqueous ophthalmic composition having a pH of 7 or more, containing a terpenoid and zinc chloride. According to the present invention, an aqueous ophthalmic composition is provided in which adsorption of the terpenoid to a container can be inhibited, thereby making it possible to inhibit the reduction in the terpenoid content for a long period of time, the aqueous ophthalmic composition having some excellent actions such as an inhibitory action for histamine release, and an inhibitory action for discharges from the eyes.

Abstract: The present invention provides nutritional compositions that are employed as oral supplementation to the human diet. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. The present invention is comprised of specific combinations of selected forms of unique sets of certain vitamins, minerals, protein, carbohydrates and phytochemicals.

Abstract: According to one embodiment, a nutritional supplement for suppressing an appetite while maintaining muscle mass of a subject during weight loss is provided. The nutritional supplement includes beta-hydroxy beta-methylbutyric acid (HMB), chromium, and Caralluma fimbriata.

Abstract: A method of measuring the effect of an active agent or a stressor on the baseline metabolic indicators of one or more hair follicles, the method including (a) obtaining one or more hair follicles; (b) placing the one or more hair follicles in a vessel, wherein the one or more hair follicles are positioned under one or more sensors; (c) using the one or more sensors to measure the one or more hair follicles' baseline metabolic indicators for both glycolysis and oxidative phosphorylation; (d) exposing the one or more hair follicles to an active agent or a stressor; and (e) using the one or more sensors to measure the one or more hair follicles' respondent metabolic indicators for both glycolysis and oxidative phosphorylation.

Abstract: Provided are compositions that contain water-soluble vitamin E derivative mixtures (compositions), such as tocopheryl polyethylene glycol succinate (TPGS), TPGS analogs, TPGS homologs and TPGS derivatives. The water-soluble vitamin E mixtures contain mixtures that include dimers and monomers of the vitamin E derivative, where the amount of dimer is greater than 12%, such as 29%, 35%, 50%, 60%, and the amount of monomer is less than 87% by weight of the water-soluble vitamin E derivative mixture. Also provided are products containing the water-soluble vitamin E derivative mixtures, including, concentrates for dilution into aqueous beverages and compositions for direct ingestion.

Abstract: Patients inflicted with various clustering chronic diseases require treatment with multiple drugs having distinct mechanisms of action. Accordingly, patients with multiple conditions suffer from cumulative side effects of multiple drugs as well as drug-drug interactions. Embodiments, agents, compounds or drugs of the present invention, such as sesquiterpenes, e.g., Zerumbone, replace an equal or larger number of approved drugs during patient treatment. Examples of disorders prevented or ameliorated by administration of the formulations of this invention include but are not limited to inflammatory diseases that may be, oncological, genetic, ischemic, infectious, neurological, hematological, ophthalmological, rheumatoid, orthopedic, neurological, hematological, kidney, vascular, dermatological, gynecological, or obstetric.

Abstract: The present invention relates to an emulsified hydrogel composition and to a production method therefor, wherein, by incorporating between 20 and 30 percent by weight of a gelling solution and an emulsion obtained by mixing between 45 and 60 percent by weight of an aqueous component and between 15 and 30 percent by weight of an oil component, it is possible to simultaneously provide the skin with an aqueous fraction and an oil fraction, and it is possible to enhance functionality due to the inclusion of a high content of a dermatologically active component dissolved in the oil component.

Abstract: The invention provides a method of treating, inhibiting and/or preventing fatty liver disease in a patient in need thereof, comprising administering an effective amount of a cyclohexenone compound of the following formula (I) to said patient,

Abstract: A method for repelling blood-sucking and biting insects, ticks and mites involving treating an object or area with a blood-sucking and biting insects, ticks and mites repelling effective amount of camphor lactams, verbenone lactams, dolicholactams, dolicholactone, and their precursors, and mixtures thereof, and optionally a carrier.

Abstract: Disclosed herein are methods of using nutritional supplements and specific combinations thereof to counteract exercise-induced stress and its sequelae in members of the Equus species. Particular embodiments focus on use of Coenzyme Q10, vitamin E and their variants. Methods include ascertaining and modifying the nutritional supplements, ascertaining and comparing health states of a horse, wherein the comparisons are made before and after modifications of the supplements and/or implementation of exercise regimens.

Abstract: The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metastasis and disorders involving increased angiogenesis, wherein R1-R6, Ra-Rc, Q, Y1, Y2 and n are as defined herein.

Abstract: Methods and compositions are disclosed for treating a subject with a disease or tissue injury mediated by cellular oxidative stress or with an environmental toxicity due to an electrophilic toxicant or pollutant, and for providing a nutritional supplement to a subject and for providing a skin treatment for a subject, where the methods comprise administering to the subject a 1,3-dicarbonyl compound.

Abstract: A dietary supplement composition is presented, which includes omega-3 fatty acids, one or more of tocopherols and tocotrienols, and/or one or more essential oils. The dietary supplement may provide numerous health benefits to the user, including improvements in cardiovascular health, ocular health, cerebral and cognitive function, muscle function, and athletic performance. This supplement also has pronounced anti-inflammatory benefits. The collective effect of the composition may also maximize the positive effects of omega-3 fatty acids while also reducing or eliminating any negative effects associated with these fats.

Abstract: Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.

Abstract: The present application provides cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives and substantially enantiomerically pure compositions thereof. These derivatives include (+)-(4S,5R)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, (?)-(4R,5S)-3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one, and salts and crystals thereof. The application further provides methods of using the disclosed compounds and compositions to activate PPAR?, activate GPR120, inhibit inflammation, and treat conditions responsive to PPAR? modulation, conditions responsive to GPR120 modulation, and metabolic disturbances such as diabetes.

Abstract: Disclosed are compounds that inhibit RNase H activity of retroviruses, for example, a compound of formula (I) wherein R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment or prevention of infection by human immunodeficiency virus (HIV).